Vela Diagnostics Signs Licensing Agreement with Stanford University for the Use of HIVdb

By Vela Diagnostics

Vela Diagnostics Signs Licensing Agreement with Stanford University for the Use of HIVdb 

2016-05-11 

Singapore (May 11, 2016) – Vela Diagnostics announced today that it has entered into a non-exclusive licensing agreement with Stanford University that will give Vela Diagnostics the rights to use HIVdb. 

Vela Diagnostics is expected to launch NGS-based Sentosa® SQ HIV Genotyping Assay in June 2016. The assay is intended for viral genotyping using plasma or serum samples, targeting Protease, Reverse Transcriptase and Integrase genes. 

“Our agreement with Stanford University puts Vela Diagnostics at the cutting edge position in molecular testing for HIV,” said Vela Diagnostics CEO Michael Tillmann. “The HIVdb will support Vela Diagnostics’ strategy to improve laboratory efficiency and bring sample-to-result solution to our customers.” 

Vela Diagnostics has also developed the Sentosa® SQ Reporter software as part of the automated Sentosa® NGS workflow. The software provides an integrated environment to analyze and manage sequencing data and is intended to automate result interpretation through secondary analysis including alignment, variant calling and genotyping. It also supports the hosting of Sentosa® SQ Reporter Browser web application that allows storing and managing run and sample information, viewing analysis reports and summary statistics, viewing audit trails and program logs, managing virtual labs, and other features to complement routine lab use. 

The early access program for Sentosa® SQ HIV Genotyping Assay is now available. If interested to enroll or to learn more, please contact gpm@veladx.com

To learn more about Sentosa® NGS workflow and test menu, visit http://www.veladx.com/products.html#ngs 

Go back